Delivery Order SPE2DB22D3010-SPE2DB24FP1PJ
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award, valued at $7,774.21, is for a delivery order to provide ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, to support military healthcare programs. The contract has an ultimate completion date of March 7, 2024. The award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support...
- This federal contract award, valued at $45,235.33, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award is a delivery order contract for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, with a completion date of May 22, 2023. The contract is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $12,252.77 for the supply of ELIQUIS 5 MG TABLET 60S. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of April 28, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued up to $999,999,999.00 and running through November...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $17,911.39 Firm Fixed Price Delivery Order is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The award has an ultimate completion date of January 31, 2024 and was made on January 30, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $22,453.68, is for the delivery of 4563416625 ELIQUIS 5 MG TABLET 60S, a prescription pharmaceutical product. The contract has a firm fixed price and an ultimate completion date of January 24, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the...
- This federal contract award, valued at $15,255.89, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, with a completion date of December 22, 2023. The award is part of a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running...
- This federal contract award, valued at $2,283.71, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of ELIQUIS 2.5 MG TABLET 60S, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) that Cencora, Inc. holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the primary...
- This federal contract award, valued at $1,390.37, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ELIQUIS 5 MG TABLET 60S, a prescription medication. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $83,681.43 Delivery Order is for the supply of ELIQUIS 5 MG TABLET 60S, a prescription medication, with an ultimate completion date of October 12, 2022. The award is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order under an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $18,406.13, is for the delivery of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, to support military and veterans' healthcare programs. The IDC with the DLA is valued at up to $999,999,999.00 and runs through November 2026, providing a comprehensive...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB24FP1PJDelivery Order
This federal contract award, valued at $22,419.85, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a delivery order for the pharmaceutical product ELIQUIS 5 MG TABLET 60S. This order is part of a larger Indefinite Delivery Contract (IDC) that Cencora, Inc. holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. The IDC serves as the primary vehicle for Cencora, Inc. to deliver a comprehensive range of pharmaceutical products and medical supplies to support the healthcare needs of the Department of Defense and other federal agencies. This particular award was not designated with a set-aside requirement, indicating open competition. The contract has a firm fixed price pricing type and an ultimate completion date of February 5, 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.4k | 2/2/24 |